Imbruvica Demonstrates 88% Response Rate In Studies of Relapsed/Refractory CLL Patients February 26, 2015Vol.38 No.02
Gazyva Increases PFS in Phase III Trial Of Indolent Non-Hodgkin’s Lymphoma Patients February 26, 2015Vol.38 No.02
Phase III MARIANNE Study Fails To Improve PFS with Kadcyla in HER2-Positive Breast Cancer February 02, 2015Vol.38 No.01
Amgen Presents Phase II and III Vectibix Studies in Wild-Type RAS Colorectal Cancer February 02, 2015Vol.38 No.01
Two Phase III LUX-Lung Trials of Gilotrif Demonstrate Benefits in Overall Survival February 02, 2015Vol.38 No.01
Phase III Jakavi Trial in Polycythemia Vera Demonstrates Control Without Phlebotomy February 02, 2015Vol.38 No.01
